How can the varied tumour FFPE blocks with HER2 ultra-low influenced on the accurate diagnosis of HER2 in breast cancer

被引：0
|
作者：
Liu, Y. [1 ]
Li, J. [1 ]
Liu, H. [1 ]
Ding, Y. [1 ]
Wu, S. [1 ]
Shang, J. [1 ]
机构：
[1] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
来源：
VIRCHOWS ARCHIV | 2024年 / 485卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
OFP-01-001
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [21] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [22] The comparison of HER2 low and HER2 0 in ductal carcinoma in situ (DCIS) for breast cancer
    Kureyama, Nari
    Kusudo, Maho
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Nozawa, Kazuki
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [23] Ultra-low fouling methylimidazolium modified surfaces for the detection of HER2 in breast cancer cell lysates
    Aube, Alexandra
    Campbell, Shirley
    Schmitzer, Andreea R.
    Claing, Audrey
    Masson, Jean-Francois
    ANALYST, 2017, 142 (13) : 2343 - 2353
  • [24] Correlation between serum HER2 extracellular domain (HER2 ECD) levels and tumour size in early, advanced and metastatic breast cancer with HER2 overexpression
    Makino, H.
    Tengan, H.
    Tatsuda, K.
    Hashidate, H.
    Mio, K.
    Kiguchi, T.
    Yamazaki, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S114 - S115
  • [25] Redefining therapeutic landscapes: clinicopathological insights into low and ultra-low HER2 expression in male breast cancer
    Jiuyan Shang
    Jiaxian Miao
    Shuyao Niu
    Xuemei Sun
    Yueping Liu
    Diagnostic Pathology, 20 (1)
  • [26] Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens
    Leitzel, K.
    Conte, P.
    Guarneri, V
    Barbieri, E.
    Huang, W.
    Ali, S. M.
    Haddad, M.
    Sperinde, J.
    Lie, Y.
    Weidler, J.
    Bates, M.
    Lipton, A.
    CANCER RESEARCH, 2009, 69 (24) : 635S - 635S
  • [27] Precision HER2: a comprehensive AI system for accurate and consistent evaluation of HER2 expression in invasive breast Cancer
    Xiong, Zhongtang
    Liu, Kai
    Liu, Shaoyan
    Feng, Jiahao
    Wang, Jin
    Feng, Zewen
    Lai, Boan
    Zhang, Qingxin
    Jiang, Qingping
    Zhang, Wei
    BMC CANCER, 2024, 24 (01)
  • [28] Examination of low Her2 expression in breast cancer
    Fernandez, Aileen I.
    Liu, Matthew
    Bellizzi, Andrew
    Brock, Jane
    Fadare, Oluwole
    Hanley, Krisztina
    Harigopal, Malini
    Jorns, Julie M.
    Kuba, M. Gabriela
    Ly, Amy
    Podoll, Mirna
    Rabe, Kimmie
    Sanders, Mary Ann
    Singh, Kamaljeet
    Snir, Olivia L.
    Soong, Rinda
    Wei, Shi
    Wen, Hannah
    Wong, Serena
    Yoon, Esther
    Pusztai, Lajos
    Reisenbichler, Emily
    Rimm, David L.
    CANCER RESEARCH, 2022, 82 (04)
  • [29] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose, Ron
    Kavuri, Shyam M.
    Searleman, Adam C.
    Shen, Wei
    Shen, Dong
    Koboldt, Daniel C.
    Monsey, John
    Goel, Nicholas
    Aronson, Adam B.
    Li, Shunqiang
    Ma, Cynthia X.
    Ding, Li
    Mardis, Elaine R.
    Ellis, Matthew J.
    CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
  • [30] Testing for HER2 in breast cancer
    Lewis, F
    Jackson, P
    Lane, S
    Coast, G
    Hanby, AM
    HISTOPATHOLOGY, 2004, 45 (03) : 207 - 217
12345